Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans (CAM)
Substance Abuse
About this trial
This is an interventional basic science trial for Substance Abuse
Eligibility Criteria
Inclusion Criteria:
- BMI of 19-26kg/m, high school education,
- fluency in English,
- resting blood pressure less than140/90mmHg and consumption of less than 4 standard alcohol or caffeinated drinks per day.
Exclusion Criteria:
- current substance abuse or lifetime substance dependence,
- regular medication,
- history of cardiovascular illness,
- current major Axis I DSM-IV disorder (APA, 2004),
- mood disorder or psychotic symptoms within the past year.
- Shift workers and pregnant or nursing mothers will also be excluded.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
Paired, high reward
Paired, low reward
Paired no reward
Unpaired, high reward
Unpaired, low reward
All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.